Clinical trials: Multicentric Breast Carcinoma
Breast Cancer
Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer
The previous reported phase I study allows us to prospectively define the optimal total dose in different metastatic locations (88).
- Trial name
- STEREO-SEIN (NCT02089100)
- Testing
- stereotactic body radiation therapy, Systemic treatment
- Where
- 18 sites in France
- Volunteers
- 154 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Breast Cancer, Node-positive Breast Cancer
TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes
Due to high pathological complete remission (pCR) rates in both breast and lymph nodes (ypT0/Tis, ypN0) following neoadjuvant systemic therapy (NST) in many patients with initially clinically node-positive (cN+) breast cancer…
- Trial name
- SenTa2 (NCT05462457)
- Testing
- Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Kliniken Essen-Mitte
Primary Non-metastatic Breast Cancer, Who Remain Disease-free
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
A significant number of patients relapse and eventually die, particularly if they were initially diagnosed with large nodes involvement and/or T3/4 diseases.
- Trial name
- NCT01805271
- Testing
- Everolimus
- Where
- 2 sites in France
- Volunteers
- 1,278 people
- Sponsor
- UNICANCER
Breast Cancer
Different Localization Techniques for Non-palpable Breast Lesions Comparison: a Retrospective and Multicentric Clinical Study
Breast conservative surgery (BCS) is nowadays the standard of care for patients affected by early breast lesions. Screening programmes led to an increase of non-palpable breast lesion detection rates.
- Trial name
- Localization01 (NCT05942105)
- Testing
- Breast conservative surgery
- Where
- Italy
- Volunteers
- 1,064 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.
Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)
Aromatase inhibitors have shown a superior efficacy compared to tamoxifen in the treatment of hormonal receptor positive breast cancer in postmenopausal patients.
- Trial name
- PreFace (NCT01908556)
- Testing
- Letrozole
- Where
- Germany
- Volunteers
- 3,545 people
- Sponsor
- Institut fuer Frauengesundheit
Triple-Negative Breast Cancer (TNBC)
Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast Cancer
This randomized, multicenter, open-label clinical study will evaluate whether adding the Fasten Onco digital therapy, which supports a fasting-mimicking diet (FMD), to standard neoadjuvant treatment can reduce treatment-related…
- Trial name
- FAST-01 (NCT07884721)
- Testing
- Fasten Onco, Standard Neoadjuvant Treatment
- Where
- 7 sites in France
- Volunteers
- 144 people
- Sponsor
- FASTEN
Breast Cancer Model, Effects of Chemotherapy
PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer
This study aims to explore new PERS prediction model can improve the pathological complete response rate of neoadjuvant chemotherapy of breast cancer and disease-free survival.
- Conditions
- Breast Cancer Model, Effects of Chemotherapy, Breast Cancer
- Trial name
- PERS (NCT03006614)
- Testing
- NVB, EPI, DDP
- Where
- China
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Shi Yanxia
Breast Cancer
Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer
Neoadjuvant chemotherapy (NAC) is increasingly used for early-stage operable breast cancer. Response of breast cancer to NAC is correlated with survival: patients who obtain greatest survival advantage are those who attain…
- Trial name
- BERNAQ (NCT02365805)
- Testing
- Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel, Epirubicin + Cisplatin + Fluorouracil, Docetaxel + Ciclofosfamide
- Where
- 7 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Endometrial Cancer, Endometrial Hyperplasia With Atypia
Endometrial Changes in Breast Cancer Women.
This is a prospective observational multicentric study. The aim is to evaluate the incidence of endometrial cancer and endometrial atypical hyperplasia in patients with previous breast cancer, treated with different adjuvant…
- Conditions
- Endometrial Cancer, Endometrial Hyperplasia With Atypia, Breast Cancer, TAM
- Trial name
- NCT05717634
- Testing
- Hysteroscopy
- Where
- Italy
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute
Breast Cancer
GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting
Non-interventional, multicenter, prospective observational study of tucatinib-trastuzumab capecitabine administered according to the standard local clinical practice following approved SmPC indication and dose.
- Trial name
- THERapy (NCT07583485)
- Where
- 30 sites in Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Oncotech
Breast Adenocarcinoma, Radiation Dermatitis
Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients
Phase III, prospective, interventional, multicentric, comparative, randomized, open study with 2 parallel arms, evaluating the efficacy of Cicaderma ointment vs standard management of each site in preventing the onset of grade >…
- Conditions
- Breast Adenocarcinoma, Radiation Dermatitis, Radiation Toxicity
- Trial name
- CICA-RT (NCT04300829)
- Testing
- cicaderma + simple hygiene rules, Simple hygiene rules and a maximum of one topical treatment
- Where
- 3 sites in France
- Volunteers
- 248 people
- Sponsor
- Centre Leon Berard
Breast Cancer
REBECCA Real-world Early BrEast CanCer mAnagement
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
- Trial name
- REBECCA (NCT06856343)
- Where
- 58 sites in France
- Volunteers
- 126 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
This study is a randomized, open-label, multicentric, phase III trial conducted in patients receiving aromatase inhibitor and palbociclib as first line therapy for estrogen receptor (ER)-positive HER2-negative metastatic breast…
- Trial name
- PADA-1 (NCT03079011)
- Testing
- Palbociclib 125mg, Aromatase Inhibitors, Fulvestrant Injectable Product
- Where
- 82 sites in France
- Volunteers
- 1,017 people
- Sponsor
- UNICANCER